Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2022-06-30 Board/Management Inform…
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Infant Bacterial Therapeutics AB appoints Maria Ekdahl as CFO
Board/Management Information Classification · 98% confidence The document is a press release dated June 30, 2022, announcing that Infant Bacterial Therapeutics AB has appointed Maria Ekdahl as the new Chief Financial Officer (CFO) effective September 19, 2022. This content directly relates to a change in senior management personnel. Based on the provided definitions, the category 'Board/Management Information (Code: MANG)' is the most appropriate fit, as it covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (2260 chars), but it is the primary announcement itself, not an announcement *about* a report.
2022-06-30 English
Infant Bacterial Therapeutics AB utser Maria Ekdahl till CFO
Board/Management Information Classification · 99% confidence The document is a press release dated June 30, 2022, announcing the appointment of Maria Ekdahl as the new Chief Financial Officer (CFO) of Infant Bacterial Therapeutics AB, effective September 19, 2022. This content directly relates to a change in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and clearly an announcement, not a comprehensive report.
2022-06-30 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding percentage and the number of shares held by 'Swedbank Robur Fonder AB' in 'Infant Bacterial Therapeutics AB'. The table structure, focusing on 'Resulting distribution of total holdings', 'Percentage of voting rights', and 'Number of underlying shares', is characteristic of a major shareholding notification. The presence of a 'Reason for major shareholding notification' further confirms this. This aligns directly with the definition for Major Shareholding Notification (MRQ). The document length is short (3177 chars), but the content is the notification itself, not an announcement of a report.
2022-05-11 English
Earnings Release 2022
Earnings Release Classification · 99% confidence The document is explicitly titled "Pressmeddelande den 4 maj, 2022" and contains a "Finansiell översikt för perioden" covering "Första kvartalet (jan-mar) 2022". It presents key financial highlights (Nettoomsättning, Rörelseresultat, Resultat per aktie) and discusses operational updates for the first quarter. This structure—a press release summarizing quarterly financial performance—is the definition of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim/Quarterly Report (IR), as it is presented as a brief press announcement with key figures, fitting the ER definition best. Q1 2022
2022-05-04 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Management Statement' for the period January 1 – March 31, 2022. It contains a CEO message, a summary of significant events, and a table of selected financial data (Net sales, Operating profit/loss, Cash flow, etc.). Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it qualifies as an Interim/Quarterly Report. Q1 2022
2022-05-04 English
Annual General Meeting of Infant Bacterial Therapeutics
AGM Information Classification · 100% confidence The document explicitly details resolutions passed during the 'Annual General Meeting of Infant Bacterial Therapeutics' held on May 4, 2022. It lists specific votes taken regarding financial statements adoption, dividend policy, board member discharge, remuneration, auditor re-election, and authorization for share issuance/incentive programs. This content directly corresponds to the materials presented or finalized at an AGM. Therefore, the appropriate classification is AGM Information (AGM-R).
2022-05-04 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.